Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19073665 | METHODS FOR USING MOSAICISM IN NUCLEIC ACIDS SAMPLED DISTAL TO THEIR ORIGIN | March 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 18932298 | SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDS | October 2024 | August 2025 | Allow | 10 | 2 | 0 | No | No |
| 18932442 | SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDS | October 2024 | September 2025 | Allow | 11 | 2 | 0 | No | No |
| 18932378 | SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDS | October 2024 | September 2025 | Allow | 11 | 2 | 0 | No | No |
| 18613618 | METHODS FOR USING MOSAICISM IN NUCLEIC ACIDS SAMPLED DISTAL TO THEIR ORIGIN | March 2024 | December 2024 | Allow | 9 | 1 | 1 | Yes | No |
| 18198763 | SEQUENCING METHODS | May 2023 | November 2024 | Allow | 18 | 2 | 1 | Yes | No |
| 18174019 | METHOD FOR ASSESSING DRUG-RESISTANT STENOTROPHOMONAS MALTOPHILIA AND DRUG-RESISTANT STENOTROPHOMONAS MALTOPHILIA ASSESSING SYSTEM | February 2023 | May 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18167803 | Methods and Systems for Analyzing Nucleic Acid Molecules | February 2023 | November 2024 | Abandon | 21 | 2 | 1 | No | No |
| 18056656 | Methods and Systems for Analyzing Nucleic Acid Molecules | November 2022 | November 2024 | Abandon | 24 | 3 | 0 | Yes | No |
| 17901826 | DIAGNOSTIC TOOL FOR SCREENING THE IMPACT OF PRODUCT INGREDIENTS FOR UROGENITAL MICROBIOMES THERAPIES | September 2022 | March 2025 | Abandon | 30 | 4 | 1 | No | No |
| 17784576 | GENERATING PROTEIN SEQUENCES USING MACHINE LEARNING TECHNIQUES BASED ON TEMPLATE PROTEIN SEQUENCES | June 2022 | September 2025 | Abandon | 39 | 4 | 1 | Yes | No |
| 17689298 | BLADDER OR BOWEL DYSFUNCTION ASSESSMENT SYSTEMS AND METHODS | March 2022 | March 2026 | Abandon | 48 | 1 | 0 | No | No |
| 17597904 | ANALYSIS METHOD FOR DETERMINING HAPLOTYPES OF FILIAL GENERATION OBJECTS AND DEVICE | January 2022 | March 2026 | Abandon | 50 | 0 | 1 | No | No |
| 17618502 | A Construction Method for Automatic Sleep Staging and Use Thereof | December 2021 | February 2026 | Abandon | 50 | 0 | 1 | No | No |
| 17643105 | BRAIN-BASED SYSTEM AND METHODS FOR EVALUATING TREATMENT EFFICACY TESTING WITH OBJECTIVE SIGNAL DETECTION AND EVALUATION FOR INDIVIDUAL, GROUP OR NORMATIVE ANALYSIS | December 2021 | January 2026 | Abandon | 50 | 1 | 0 | No | No |
| 17494632 | Early Detection of Cancer, Recurrence Monitoring and Companion Diagnostics via Liquid Biopsy | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17394591 | SYSTEMS AND METHODS FOR MODELLING PHYSIOLOGIC FUNCTION USING A COMBINATION OF MODELS OF VARYING DETAIL | August 2021 | September 2025 | Allow | 50 | 1 | 0 | Yes | No |
| 17374000 | SYSTEMS AND METHODS FOR DETERMINING NUCLEIC ACIDS | July 2021 | November 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17159725 | TRANSCRIPTION FACTOR PROFILING | January 2021 | March 2026 | Allow | 60 | 7 | 1 | Yes | No |
| 17129054 | METHOD FOR DISCOVERING PHARMACOGENOMIC BIOMARKERS | December 2020 | January 2026 | Abandon | 60 | 1 | 0 | No | No |
| 17109723 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | December 2020 | February 2026 | Allow | 60 | 1 | 1 | Yes | No |
| 17049667 | MOLECULAR TYPING OF MULTIPLE MYELOMA AND APPLICATION | October 2020 | October 2024 | Allow | 48 | 1 | 1 | No | No |
| 17075690 | Methods for Introducing Mutations That Alter the Probability of Intranucleic Acid Base Pairing of a Conserved Structured Nucleotide and Related Compositions | October 2020 | September 2025 | Abandon | 59 | 0 | 1 | No | No |
| 17070668 | GENE EXPRESSION SIGNATURE OF HYPERPROGRESSIVE DISEASE (HPD) IN PATIENTS AFTER ANTI-PD-1 IMMUNOTHERAPY | October 2020 | March 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17017441 | GENETIC ANALYSIS METHOD | September 2020 | June 2025 | Abandon | 57 | 0 | 1 | No | No |
| 16985980 | METHODS OF QUALITY CONTROL USING SINGLE-NUCLEOTIDE POLYMORPHISMS IN PRE-IMPLANTATION GENETIC SCREENING | August 2020 | March 2026 | Allow | 60 | 2 | 1 | Yes | No |
| 16963385 | METHOD AND SYSTEM FOR SIGNAL PROCESSING REHABILITATION EXERCISE SIGNALS | July 2020 | August 2025 | Allow | 60 | 1 | 1 | Yes | No |
| 16889917 | PULSE CALLER AND BASE CALLER | June 2020 | January 2025 | Allow | 56 | 1 | 1 | Yes | No |
| 15929970 | METHODS, SYSTEMS, AND COMPUTER-READABLE MEDIA FOR ACCELERATED BASE CALLING | June 2020 | October 2024 | Allow | 53 | 1 | 1 | No | No |
| 16874215 | METHYLATION PATTERN ANALYSIS OF HAPLOTYPES IN TISSUES IN A DNA MIXTURE | May 2020 | May 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16837210 | DETECTING GENETIC COPY NUMBER VARIATION | April 2020 | August 2024 | Allow | 52 | 2 | 0 | No | No |
| 16819190 | SYSTEM, METHOD AND SOFTWARE FOR CALCULATION OF CANNABIS DRUG EFFICIENCY INDEX (CDEI) | March 2020 | December 2022 | Abandon | 33 | 1 | 1 | No | No |
| 16793405 | SYSTEM AND METHOD FOR MANAGING GENOMIC TESTING RESULTS | February 2020 | January 2025 | Abandon | 59 | 1 | 1 | No | No |
| 16627193 | SYSTEMS AND METHODS FOR MHC CLASS II EPITOPE PREDICTION | December 2019 | March 2025 | Allow | 60 | 2 | 1 | Yes | No |
| 16669270 | METHODS AND COMPOSITIONS FOR GERMLINE VARIANT DETECTION | October 2019 | July 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16597707 | METHODS AND PROCESSES FOR NON-INVASIVE ASSESSMENT OF GENETIC VARIATIONS | October 2019 | August 2024 | Allow | 58 | 2 | 0 | Yes | No |
| 16590303 | METHODS AND SYSTEMS FOR VISUALIZING AND EVALUATING DATA | October 2019 | August 2024 | Allow | 58 | 2 | 0 | No | No |
| 16579508 | COMPUTER-IMPLEMENTED SYSTEM AND METHOD FOR IDENTIFYING SIMILAR PATIENTS | September 2019 | March 2025 | Allow | 60 | 2 | 1 | Yes | Yes |
| 16562312 | METHODS FOR GENOME ASSEMBLY, HAPLOTYPE PHASING, AND TARGET INDEPENDENT NUCLEIC ACID DETECTION | September 2019 | August 2025 | Abandon | 60 | 4 | 0 | Yes | No |
| 16554286 | CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF | August 2019 | September 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16450775 | GENOME EXPLORER SYSTEM TO PROCESS AND PRESENT NUCLEOTIDE VARIATIONS IN GENOME SEQUENCE DATA | June 2019 | September 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16433380 | METHODS, SYSTEMS, COMPUTER READABLE MEDIA, AND KITS FOR SAMPLE IDENTIFICATION | June 2019 | July 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16428656 | SEQUENCING METHODS | May 2019 | June 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16411849 | METHOD AND SYSTEM FOR IDENTIFICATION OF KEY DRIVER ORGANISMS FROM MICROBIOME / METAGENOMICS STUDIES | May 2019 | September 2024 | Allow | 60 | 2 | 1 | Yes | No |
| 16285604 | METHODS FOR TREATING BARRETT'S METAPLASIA AND ESOPHAGEAL ADENOCARCINOMA | February 2019 | September 2023 | Allow | 55 | 2 | 0 | No | No |
| 16245343 | METHODS FOR FLOW SPACE QUALITY SCORE PREDICTION BY NEURAL NETWORKS | January 2019 | February 2025 | Abandon | 60 | 4 | 0 | No | No |
| 16241288 | PROCESS FOR ALIGNING TARGETED NUCLEIC ACID SEQUENCING DATA | January 2019 | August 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16065982 | SYSTEM AND METHOD FOR ANALYZING GENOTYPE USING GENETIC VARIATION INFORMATION ON INDIVIDUAL'S GENOME | November 2018 | March 2026 | Abandon | 60 | 10 | 0 | Yes | No |
| 16093588 | DETECTING CANCER DRIVER GENES AND PATHWAYS | October 2018 | March 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16119961 | IDENTIFYING FALSE POSITIVE VARIANTS USING A SIGNIFICANCE MODEL | August 2018 | August 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16033983 | GRANULAR ELECTION OF PREDICTIVE POLYGENIC MODELS | July 2018 | February 2020 | Abandon | 19 | 6 | 1 | Yes | Yes |
| 15771288 | METHOD AND SYSTEM FOR SELECTING CUSTOMIZED DRUG USING GENOMIC NUCLEOTIDE SEQUENCE VARIATION INFORMATION AND SURVIVAL INFORMATION OF CANCER PATIENT | May 2018 | October 2024 | Abandon | 60 | 4 | 1 | No | No |
| 15768939 | Multiallelic Genotyping of Single Nucleotide Polymorphisms and Indels | April 2018 | September 2025 | Abandon | 60 | 5 | 1 | No | No |
| 15766733 | METHODS AND APPLICATIONS OF GENE FUSION DETECTION IN CELL-FREE DNA ANALYSIS | April 2018 | December 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 15947463 | System for Diagnosing of Avellino Corneal Dystrophy | April 2018 | April 2022 | Allow | 48 | 5 | 1 | Yes | No |
| 15763577 | Typing and Assembling Discontinuous Genomic Elements | March 2018 | August 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 15838724 | Applied Computer Technology for Management, Synthesis, Visualization, and Exploration of Parameters in Large Multi-Parameter Data Sets | December 2017 | January 2025 | Allow | 60 | 5 | 1 | Yes | No |
| 15660858 | Nervous System Modeling Tool | July 2017 | November 2023 | Abandon | 60 | 4 | 1 | Yes | No |
| 15408402 | METHODS FOR MAKING GENETIC REGULATORY ELEMENTS | January 2017 | August 2024 | Allow | 60 | 7 | 1 | Yes | No |
| 15331792 | NOVEL CRISPR ENZYMES AND SYSTEMS | October 2016 | April 2024 | Allow | 60 | 7 | 1 | No | No |
| 14775252 | METHODS AND SYSTEMS FOR ALIGNING REPETITIVE DNA ELEMENTS | September 2015 | June 2025 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 14743713 | STRING GRAPH ASSEMBLY FOR POLYPLOID GENOMES | June 2015 | September 2024 | Allow | 60 | 8 | 1 | No | No |
| 14651349 | METHOD TO CALCULATE FREE ENERGIES | June 2015 | March 2020 | Abandon | 57 | 8 | 1 | Yes | Yes |
| 14470628 | Identifying Possible Disease-Causing Genetic Variants by Machine Learning Classification | August 2014 | November 2025 | Abandon | 60 | 7 | 1 | No | Yes |
| 14355408 | Method And System For Detection Of An Organism | April 2014 | July 2016 | Abandon | 27 | 9 | 1 | Yes | Yes |
| 14229321 | Method and System for Matching Probabilistic Identitypes on a Database | March 2014 | May 2021 | Abandon | 60 | 10 | 1 | No | Yes |
| 13912318 | Systems and Methods for Automatically Displaying Patterns in Biological Monitoring Data | June 2013 | February 2024 | Allow | 60 | 6 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WOITACH, JOSEPH T.
With a 25.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 6.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner WOITACH, JOSEPH T works in Art Unit 1687 and has examined 54 patent applications in our dataset. With an allowance rate of 59.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner WOITACH, JOSEPH T's allowance rate of 59.3% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by WOITACH, JOSEPH T receive 3.54 office actions before reaching final disposition. This places the examiner in the 94% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WOITACH, JOSEPH T is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +38.5% benefit to allowance rate for applications examined by WOITACH, JOSEPH T. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 23.5% of cases where such amendments are filed. This entry rate is in the 31% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 2% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 50.0% of appeals filed. This is in the 14% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 95.5% are granted (fully or in part). This grant rate is in the 89% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.